Increased expression of fibulin-3 was found to inhibit TGF-β-induced epithelial–mesenchymal transition (EMT) and endothelial permeability in breast cancer, as well as cell morphology, proliferation, encroachment, adhesion, and migration [7,8], whereas the loss of expression or function of fibulin-3 promoted these TGF-β-mediated effects [9]. The gene discussed is EFEMP1; the disease is breast carcinoma.